Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
3.
J Dermatol ; 43(6): 591-619, 2016 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-26972937

RESUMEN

We aimed to prepare guidelines for the management of diabetic ulcer/gangrene with emphasis on the diagnosis and treatment of skin symptoms. They serve as a tool to improve the quality of the diagnosis and treatment in each patient and, further, to improve the level of the care for diabetic ulcer in Japan by systematically presenting evidence-based recommendations for clinical judgments by incorporating various viewpoints.


Asunto(s)
Pie Diabético/terapia , Gangrena/terapia , Aldehído Reductasa/antagonistas & inhibidores , Antibacterianos/administración & dosificación , Eliminación de Componentes Sanguíneos , Desbridamiento , Pie Diabético/complicaciones , Pie Diabético/diagnóstico , Nefropatías Diabéticas/diagnóstico , Gangrena/diagnóstico , Gangrena/etiología , Humanos , Oxigenoterapia Hiperbárica , Isquemia/diagnóstico , Isquemia/etiología , Terapia de Presión Negativa para Heridas , Aparatos Ortopédicos , Osteomielitis/diagnóstico por imagen , Osteomielitis/tratamiento farmacológico , Osteomielitis/etiología , Diálisis Renal/efectos adversos , Cicatrización de Heridas
4.
J Dermatol ; 43(9): 989-1010, 2016 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-26971391

RESUMEN

Burns are a common type of skin injury encountered at all levels of medical facilities from private clinics to core hospitals. Minor burns heal by topical treatment alone, but moderate to severe burns require systemic management, and skin grafting is often necessary also for topical treatment. Inappropriate initial treatment or delay of initial treatment may exert adverse effects on the subsequent treatment and course. Therefore, accurate evaluation of the severity and initiation of appropriate treatment are necessary. The Guidelines for the Management of Burn Injuries were issued in March 2009 from the Japanese Society for Burn Injuries as guidelines concerning burns, but they were focused on the treatment for extensive and severe burns in the acute period. Therefore, we prepared guidelines intended to support the appropriate diagnosis and initial treatment for patients with burns that are commonly encountered including minor as well as moderate and severe cases. Because of this intention of the present guidelines, there is no recommendation of individual surgical procedures.


Asunto(s)
Quemaduras/diagnóstico , Quemaduras/terapia , Fluidoterapia/métodos , Índice de Severidad de la Enfermedad , Cicatrización de Heridas , Administración Cutánea , Corticoesteroides/administración & dosificación , Corticoesteroides/uso terapéutico , Antibacterianos/uso terapéutico , Antiinfecciosos Locales/uso terapéutico , Vendajes , Broncoscopía , Quemaduras/clasificación , Quemaduras por Inhalación/diagnóstico , Quemaduras por Inhalación/terapia , Humanos , Hidroterapia , Pulmón/diagnóstico por imagen , Pomadas/administración & dosificación , Pomadas/uso terapéutico , Pronóstico , Radiografía , Sulfadiazina de Plata/uso terapéutico , Tétanos/prevención & control , Toxoide Tetánico/uso terapéutico , Infección de Heridas/prevención & control
5.
J Dermatol ; 43(1): 4-8, 2016 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-26782000

RESUMEN

Psoriasis is a chronic inflammatory skin disease characterized by a significant deterioration in the quality of life of affected individuals. Notably, psoriasis is significantly associated with cardiovascular and metabolic syndrome and other autoimmune disorders. Recent progress in biologic therapies has revealed the fundamental role of tumor necrosis factor-α, interleukin (IL)-23 and the IL-17A axis together with aberrant overproduction of epidermal IL-36γ in the pathogenesis of psoriasis. This review provides an update on the clinical, pathological and therapeutic advancements involving psoriasis.


Asunto(s)
Psoriasis , Autoinmunidad , Productos Biológicos/uso terapéutico , Terapia Biológica , Humanos , Psoriasis/etiología , Psoriasis/inmunología , Psoriasis/terapia
6.
J Dermatol Sci ; 74(3): 251-9, 2014 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-24630239

RESUMEN

BACKGROUND: Rapamycin has been shown to exert an anti-fibrotic effect on skin fibrosis in a certain subset of patients with systemic sclerosis (SSc) and in bleomycin-treated animal models. OBJECTIVES: To investigate the mechanism responsible for the anti-fibrotic effect of rapamycin especially by focusing on human α2(I) collagen (COL1A2) and matrix metalloproteinase 1 (MMP1) genes in normal and systemic sclerosis (SSc) dermal fibroblasts. METHODS: The expression levels of type I procollagen and MMP1 proteins were analyzed by immunoblotting and the mRNA levels of COL1A2 and MMP1 genes were evaluated by quantitative real-time RT-PCR. The activities of COL1A2 and MMP1 promoters were determined by reporter analysis. RESULTS: Rapamycin significantly decreased the levels of type I procollagen protein and COL1A2 mRNA, while significantly increasing the levels of MMP1 protein and mRNA in normal dermal fibroblasts. Similar effects of rapamycin were also observed in SSc dermal fibroblasts. Importantly, the inhibitory and stimulatory effects of rapamycin on the mRNA levels of COL1A2 and MMP1 genes, respectively, were significantly greater in SSc dermal fibroblasts than in normal dermal fibroblasts. In SSc dermal fibroblasts, rapamycin affected the expression of COL1A2 gene at the post-transcriptional level. In contrast, rapamycin altered the expression of MMP1 gene at the transcriptional level through the JNK/c-Jun signaling pathway in those cells. CONCLUSION: Rapamycin has a potential to directly regulate the deposition of type I collagen in extracellular matrix through inhibiting type I collagen synthesis and promoting its degradation by MMP1, suggesting that this drug is useful for the treatment of SSc.


Asunto(s)
Colágeno Tipo I/metabolismo , Inmunosupresores/uso terapéutico , Metaloproteinasa 1 de la Matriz/metabolismo , Esclerodermia Sistémica/tratamiento farmacológico , Sirolimus/uso terapéutico , Supervivencia Celular , Células Cultivadas , Colágeno Tipo I/genética , Evaluación Preclínica de Medicamentos , Fibroblastos/efectos de los fármacos , Fibroblastos/metabolismo , Expresión Génica/efectos de los fármacos , Humanos , Inmunosupresores/farmacología , Metaloproteinasa 1 de la Matriz/genética , Esclerodermia Sistémica/metabolismo , Sirolimus/farmacología
7.
J Invest Dermatol ; 132(3 Pt 1): 667-76, 2012 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-22071476

RESUMEN

The lymph transports tissue-resident dendritic cells (DCs) to regional lymph nodes (LNs), having important roles in immune function. The biological effects on tissue inflammation following lymphatic flow obstruction in vivo, however, are not fully known. In this study, we investigated the role of the lymphatic system in contact hypersensitivity (CHS) responses using k-cyclin transgenic (kCYC(+/-)) mice, which demonstrate severe lymphatic dysfunction. kCYC(+/-) mice showed enhanced ear swelling to both DNFB and FITC, as well as stronger irritant responses to croton oil compared with wild-type littermates. Consistently, challenged ears of kCYC(+/-) mice exhibited massive infiltrates of inflammatory cells. In contrast, DC migration to regional LNs, drainage of cell-free antigen to LNs, antigen-specific IFN-γ production, and lymphocyte proliferation were impaired during the sensitization phase of CHS in kCYC(+/-) mice. Transfer experiments using lymphocytes from sensitized mice and real-time PCR analysis of cytokine expression using challenged ear revealed that ear swelling was enhanced because of impaired lymphatic flow. Collectively, we conclude that insufficient lymphatic drainage augments apparent inflammation to topically applied allergens and irritants. The findings add insight into the clinical problem of allergic and irritant contact dermatitis that commonly occurs in humans with peripheral edema of the lower legs.


Asunto(s)
Alérgenos/inmunología , Dermatitis Alérgica por Contacto/inmunología , Inmunización/efectos adversos , Sistema Linfático/inmunología , Animales , Movimiento Celular/inmunología , Aceite de Crotón/farmacología , Citocinas/biosíntesis , Citocinas/inmunología , Células Dendríticas/inmunología , Dermatitis Alérgica por Contacto/patología , Dinitrofluorobenceno/inmunología , Dinitrofluorobenceno/farmacología , Edema/inmunología , Fluoresceína-5-Isotiocianato/farmacología , Interferón gamma/biosíntesis , Interferón gamma/inmunología , Irritantes/inmunología , Irritantes/farmacología , Sistema Linfático/patología , Activación de Linfocitos/inmunología , Linfocinas , Ratones , Ratones Transgénicos
8.
Eur J Immunol ; 36(8): 2116-27, 2006 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-16856206

RESUMEN

CC chemokine ligand (CCL)17 is implicated in the pathogenesis of atopic dermatitis (AD). To study the effect of CCL17 produced by keratinocytes (KC) during inflammation, we created transgenic (Tg) mice in which CCL17 is overexpressed in KC. Th2-type contact hypersensitivity (CHS) was enhanced and Th1-type CHS was suppressed in these mice. Increased numbers of CC chemokine receptor (CCR)4(+) cells and mast cells infiltrated in Tg mice. Levels of IL-4 mRNA were higher and those of IFN-gamma mRNA were lower in both acute and chronic CHS. Higher levels of serum IgE were observed after CHS. Numbers of CCR4(+) cells among PBMC were increased in Tg mice challenged acutely on the trunk. Chronic irritation with croton oil induced dermatitis and an elevation of serum IgE levels. Tg mice showed enhanced ear swelling after tape stripping. CCL17 was thought to modify the inflammation caused by sensitizing reagents as well as irritant reagents by attracting CCR4(+) cells into the lesional skin and creating a Th2-dominant condition. AD-like conditions such as increased number of mast cells and elevated levels of serum IgE were observed. Thus, CCL17 may participate in the pathogenesis of skin diseases such as AD by regulating both allergic and irritant inflammation.


Asunto(s)
Quimiocinas CC/metabolismo , Hipersensibilidad/inmunología , Hipersensibilidad/metabolismo , Células Th2/inmunología , Células Th2/metabolismo , Enfermedad Aguda , Animales , Células Cultivadas , Quimiocina CCL17 , Quimiocinas CC/genética , Enfermedad Crónica , Aceite de Crotón/farmacología , Dermatitis por Contacto/genética , Dermatitis por Contacto/inmunología , Dermatitis por Contacto/metabolismo , Dermatitis por Contacto/patología , Femenino , Regulación de la Expresión Génica , Hipersensibilidad/genética , Hipersensibilidad/patología , Interferón gamma/genética , Interleucina-4/genética , Queratinocitos/metabolismo , Recuento de Linfocitos , Linfocitos/citología , Linfocitos/efectos de los fármacos , Linfocitos/metabolismo , Masculino , Ratones , Ratones Transgénicos , Oxazoles/farmacología , ARN Mensajero , Receptores CCR4 , Receptores de Quimiocina , Factores de Transcripción/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA